Risk Factors Update Summary
- Restating financial statements for 2022 to correct errors, increasing loss from $24 million to $39 million.
- Identified material weaknesses in internal controls over financial reporting and clinical trial expenses.
- Increased accumulated deficit from $91 million to $134 million as of December 31, 2023.
- Increased negative cash flow from operations from $19 million to $28 million as of December 31, 2023.
- Increased cash and cash equivalents from $18 million to $23 million as of December 31, 2023.
Full Text Changes in Most Recent 10-K
Intended use: review the highlighted statements. These are additions to the risk factors disclosure in the most recent 10-K filing compared to the previous 10-K filing. Deleted and moved text is less important and is shown for context.
To view the full company filings, click on the following link to be taken to the SEC EDGAR database landing page for the company: https://www.sec.gov/edgar/browse/?CIK=1742927&owner=exclude
This content requires a 'Free' membership to view. Please create one here.
This content requires a 'Free' membership to view. Please create one here.